Funding Fuels Hiring
A biology startup built on expeditions to thermal springs and polar ice has secured the compute muscle of the world's most valuable chipmaker. The result is playing out in laboratory hiring queues across the UK.
Basecamp Research closed a $60 million Series B in October 2024 led by Singular, bringing total capital raised to $85 million. S32 and redalpine joined, along with strategic individuals including Roche vice-chairman André Hoffmann, former Philips CEO Feike Sijbesma, and former Unilever CEO Paul Polman. PitchBook valued the company at $71 million in 2022. Since that financing, Basecamp announced the Trillion Gene Atlas — a multi-partner collaboration with NVIDIA, Anthropic, PacBio, and Ultima Genomics targeting a 100-fold expansion of its proprietary BaseGraph dataset over two years.
Co-founders Glen Gowers and Oliver Vince, both Oxford biology PhDs, built the company's early reputation on a mobile DNA sequencing lab they ran from an ice cap. That field-first approach — expeditions to over 200 sites across more than 30 countries, has already yielded more than a million species new to science and over 10 billion novel genes, roughly ten times the content of every public database combined. Scaling that pipeline from billions to a trillion genes requires wet-lab throughput that no amount of cloud compute can replace.
Gowers has described the company's compute cluster as possibly the largest dedicated to the natural world, but he has also emphasized that data generation remains the bottleneck. "Biology has been fundamentally data-starved," Ultima Genomics CEO Gilad Almogy said in the Atlas announcement, noting that public repositories represent less than one hundred-thousandth of one percent of life on Earth. Basecamp's answer is to keep sending teams into the field and to build the lab capacity that turns those field samples into training-grade sequence data.
The funding also underwrites a shift from pure discovery to applied partnerships. Procter & Gamble uses Basecamp models to design cold-water enzymes; Colorifix taps them for sustainable fabric dyes. Gowers told TechCrunch the plan is to "continue building the startup, both through partnerships … and by amassing more data to expand its models."
The Wet-Lab Bottleneck
The jump from 10 billion genes to a trillion is not a computing problem. It is a wet-lab problem. Basecamp's Trillion Gene Atlas targets a 100-fold expansion of BaseData over two years, meaning genomic material from more than 100 million new species across thousands of sites worldwide.
Basecamp's origin story is inseparable from that bench work. In a 2025 interview, Vince described hauling a portable lab across an ice cap by sledge for weeks, running fully off-grid DNA sequencing to discover microbes never seen before — half of them with completely unknown function. That expedition model has since scaled to partnerships in 27 countries and more than 150 locations: thermal springs, deep-sea sediment, polar ice, remote high-altitude plateaus, volcanoes, the bottom of the sea.
The Ultima Genomics UG200 series, selected for the Atlas in March 2026, is built for exactly this scale: low-cost, high-volume sequencing that turns thousands of environmental samples into terabases of raw data. Public databases are heavily biased toward lab model organisms. Models trained on them — AlphaFold2 included, work well for well-represented proteins but struggle with the large, complex, underrepresented structures that dominate novel biology. Basecamp's EDEN and BaseFold models bypass this "data wall" by training entirely on BaseData, which is already more than ten times larger than all public resources combined. The Trillion Gene Atlas aims to widen that lead another two orders of magnitude.
Gowers has said the breadth of natural genetic information — estimated at 99 percent unknown, means humans "don't even have the capacity to ask the right questions." The AI is meant to ask them. But the AI only sees what the wet lab delivers. The Series B funding, with NVIDIA's participation, is being deployed in part to grow the laboratory team that can keep the sequencers fed.
Rivals Scramble
Basecamp's Trillion Gene Atlas push has forced the AI-biologics field to confront a data-scale problem it can no longer sidestep. The London-based startup's dataset — already roughly ten times the size of every public database combined, paired with a stated goal to scale BaseData 100-fold in two years, has made wet-lab throughput a strategic bottleneck for every competitor building "physical AI" platforms.
Insitro, the San Francisco company founded by Daphne Koller and last valued at $2.5 billion, illustrates the tension. In May 2025 the company cut 22 percent of its workforce — about 65 people, leaving roughly 230 employees, a move leadership framed as extending runway into 2027 while advancing first-in-class metabolic and neuroscience programs toward clinic readiness in 2026. Yet the same announcement highlighted three strategic agreements with Eli Lilly signed in October 2024, including an option to in-license a clinical-stage GalNAc delivery platform for two siRNA therapies and a collaboration on an antibody program. In March 2025 Insitro added a partnership with the INSIGHT Health Data Research Hub at Moorfields Eye Hospital in London to build a novel AI foundation model.
Zero G Talent's board shows Insitro adding two roles in the past seven days alone — a Chief Medical Officer ($450–480k) and a Vice President of Regulatory Affairs ($313–333k), alongside open requisitions for a VP of Bioassays, Cell Models, and Genomic Screening ($290–326k) and a Senior Director of Translational Medicine and Diagnostics ($224–299k). The hiring skew towards late-stage clinical and regulatory talent signals a pivot from pure discovery to IND-enabling work, even as headcount shrinks.
| Role | Salary Band (USD) |
|---|---|
| Chief Medical Officer | $450–480k |
| VP Regulatory Affairs | $313–333k |
| VP Bioassays, Cell Models, Genomic Screening | $290–326k |
| Senior Director Translational Medicine & Diagnostics | $224–299k |
| Median (all roles) | $238k |
Recursion Pharmaceuticals, the other public-market standard-bearer for AI-driven drug discovery, has not disclosed new facility builds or technician hiring targets comparable to Basecamp's London-centric push. Its partnership with Roche/Genentech on neuroscience targets continues to deepen. Without fresh capital-expenditure guidance or site-level headcount data, any claim of Recursion scaling wet-lab capacity remains speculative.
The broader pattern is clearer than any single headcount number. Basecamp's biodiversity-first data engine — now integrated with NVIDIA BioNeMo and Anthropic's Claude Science, has raised the bar for training-set scale. Insitro's 20-plus petabytes of automated cellular experiments and its Virtual Human causal engine were built on a different premise: human genetics anchored in cellular perturbation. Basecamp's trillion-gene ambition reframes the competition around evolutionary diversity rather than human-centric data alone.
A Talent Pool Under Strain
Basecamp's London headquarters sits in a dense UK life-sciences cluster competing for technicians who can run high-throughput sequencing, manage automated liquid-handling platforms, and maintain sample integrity. When a well-capitalized player adds wet-lab roles, the ripple reaches contract research organizations, university core facilities, and NHS genomics labs that share recruitment channels.
Technicians who can troubleshoot sequencing runs, optimize library prep for low-input environmental DNA, and feed clean data into GPU clusters are scarce. UK universities produce graduates with theoretical molecular biology training, but hands-on experience with automation stacks deployed at scale remains concentrated in a handful of industrial placements. Insitro's senior bioassays role tops out at $326,000; while that position is US-based, it signals the valuation the market places on wet-lab expertise that bridges biology and compute.
The UK BioIndustry Association has flagged a technician shortfall across the life-sciences sector, with the sharpest deficits in genomics and high-throughput screening. Contract research organizations have responded by launching internal upskilling programs, but the lead time to produce a fully autonomous automation technician is 12–18 months. Apprenticeship standards for laboratory scientist and bioinformatics technician roles have been updated, yet uptake remains low because employers need deployed staff now. The Migration Advisory Committee added biological scientist to the Shortage Occupation List, easing visa sponsorship, but the visa route does not solve the experience mismatch — overseas candidates often lack familiarity with the specific instrument fleets and data pipelines UK firms run.
Basecamp's job postings list requirements that blend molecular biology, Python scripting, and LIMS administration, a hybrid profile that barely existed five years ago. The company has begun recruiting from adjacent sectors: former pharmaceutical QC labs, agricultural biotech, even food-safety testing facilities where high-throughput PCR and robotics are standard. This cross-sector pull thins the talent pool for those industries in turn.
Technician roles stay open for months, project timelines stretch, and companies bid against each other for qualified candidates in the Greater London–Cambridge–Oxford triangle. Until training capacity catches up (or automation itself reduces the per-experiment technician burden), the labor constraint will remain a hard ceiling on how fast the Trillion Gene Atlas, and the UK's AI-biologics sector more broadly, can scale.
Policy as Accelerant
The hiring surge at Basecamp and its peers is not unfolding in a policy vacuum. Deloitte's 2026 survey of 280 C-suite executives across biopharma and medtech (spanning the US, Europe, and Asia) found that regulation was the single most frequently cited trend expected to shape organizational strategy. Fifty-one percent of non-US respondents pointed to national regulatory changes (including the EU AI Act, the Corporate Sustainability Reporting Directive, the European Health Data Space, and China's volume-based procurement program) as factors that could affect market access, pricing, and reimbursement models.
The same survey shows accelerated digital transformation and AI adoption climbing the agenda. Forty-eight percent of respondents identified accelerated digital transformation as a trend likely to have substantial impact in 2026 (a statistically significant increase over the prior year) while 41 percent flagged the proliferation of generative AI and 30 percent cited agentic AI as influential. Yet only 22 percent of life sciences leaders said they have successfully scaled AI, and just 9 percent reported achieving significant returns.
UK-specific incentives do not appear as line items in the Deloitte data, but the survey's European cohort (which includes UK respondents) reported that 90 percent of biopharma leaders in surveyed European and Asian countries hold "positive" or "cautiously positive" expectations for the coming year. That sentiment aligns with the UK government's stated ambition to make the country a science superpower. Companies such as Basecamp, Insitro, and Recursion (each expanding wet-lab footprints while scaling AI platforms) are the private-sector counterpart to those public commitments.
Deloitte's analysis estimates that AI investments by biopharma companies over the next five years could generate up to 11 percent in value relative to revenue across functional areas; for medtech, implementation could yield cost savings of up to 12 percent of total revenue within two to three years.
The competition for skilled labor remains intense. More than a third of 600 manufacturing executives in a 2025 Deloitte survey cited "equipping workers with the skills and knowledge they need to maximize the potential of smart manufacturing and operations" as their top concern. In life sciences, 29 percent of biopharma leaders and 31 percent of medtech leaders plan to use AI tools or training to improve workforce productivity. That dual pressure (regulatory compliance and productivity demand) funnels hiring towards hybrid roles: molecular biology technicians who can annotate training data, automation engineers who can validate AI-driven liquid-handling protocols, and data stewards who can satisfy the European Health Data Space's interoperability requirements.
Boston Beckons
Basecamp's London headquarters has always been a launchpad, not a boundary. The company's multi-year collaboration with Dr. David R. Liu and the Broad Institute (a biomedical research center spanning MIT and Harvard in Cambridge, Massachusetts) creates a de facto scientific bridge between the UK and the Boston biotech corridor. That partnership, announced alongside the $60 million Series B in October 2024, puts Basecamp's proprietary BaseData and EDEN models directly into the hands of researchers engineering novel fusion proteins and large-molecule genetic medicines at one of the world's densest concentrations of academic and commercial life-sciences talent.
The Broad Institute relationship is more than a publishing partnership. Liu's lab is actively using Basecamp's datasets to develop genetic medicines, which means Basecamp scientists and engineers are already working across time zones with Boston-based collaborators on shared computational and experimental workflows. The Series B investor syndicate reinforced this transatlantic axis: alongside European lead Singular, the round included S32 (San Francisco), redalpine (Zurich/Berlin), and strategic individuals such as Hoffmann and Polman, whose networks span both continents.
Since that financing, the Trillion Gene Atlas initiative has formalized the compute-and-data infrastructure that makes cross-site work scalable. The Atlas partnership is designed to generate genomic data from over 100 million species across thousands of global sites. The Broad Institute's existing sequencing capacity and Basecamp's plan to optimize and productionize its BaseFold structure-prediction model for NVIDIA BioNeMo create demand for engineers and scientists who can sit at the intersection of Basecamp's proprietary data stack and NVIDIA's platform, roles that could be based in London, Boston, or split between them.
The company's biodiversity sampling network already operates as a distributed laboratory. Mobile DNA sequencing units pioneered on an ice cap have been adapted into compact field modules. That same modular logic applies to talent: the skills needed to run high-throughput sequencing, manage metadata integrity, and feed clean data into AI training pipelines are portable. As the Atlas scales toward its trillion-gene target, the hiring plan logically extends beyond London to wherever the sequencing instruments and the compute clusters concentrate. Boston, with its cluster of sequencing cores, cloud GPU capacity, and a labor market steeped in both molecular biology and machine learning, is the obvious second pole.
No public filing or press release has yet announced a leased laboratory address in the Seaport or a headcount target for a Boston site. But the structural incentives are aligned: the Broad collaboration provides scientific anchor; the NVIDIA-BioNeMo integration provides compute anchor; the Ultima deployment roadmap provides instrumentation anchor. For job seekers, the signal is clear: the same funding round that is expanding London lab-technician benches is also creating demand for scientists who can translate between Basecamp's London-built data engine and the Boston ecosystem where much of the downstream therapeutic development happens. From thermal springs to the Boston corridor, the field-first logic that put a mobile lab on an ice cap is now building a transatlantic talent pipeline.
Working in frontier tech? Zero G Talent tracks the openings: see every open Insitro role, browse frontier tech jobs, the companies hiring, and the people building the field.